This study is for patients with newly diagnosed, localized, and advanced Head and Squamous Cell Carcinoma and whose doctor has recommended surgery.

Multi-Center Registry of Patients with Sarcoidosis-Associated Pulmonary Hypertension (ReSAPH)

Patients with PAH (Group 1) will be recruited to the National Institutes of Health (NIH) and enrolled in this natural history study investigating the ability of circulating markers of vascular inflammation as well as high-resolution cardiac magnetic resonance imaging (MRI) to accurately stage severity of disease and/or predict clinically relevant outcomes.

This phase II MATCH trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors, lymphomas, or multiple myeloma.

The first few months and years of a child’s life are essential in shaping the intestinal microbiome which rapidly develops during this time, reaching a relative stability by toddlerhood that generally lasts into adulthood. Hence this early period may be critical for shaping future health and preventing the development of many diseases. Even prior to birth, factors have been identified that may affect the early microbiome development. Premature infants are at increased risk of an imbalance in gut bacteria and delayed or disturbed gut colonization for many reasons including an immature gut and immune system, increased exposure to antibiotics and delayed feeding. They are also at increased risk of many disorders associated with gut bacteria imbalance compared to infants who are born full term. At Inova Translational Medicine Institute (ITMI) we are conducting a longitudinal microbiome study of babies born prematurely and in the neonatal intensive care unit (NICU) and following then into early childhood to examine why and how disturbances in gut bacteria develop and how they may lead to early childhood health problems such as necrotizing enterocolitis, obesity and allergies. Using the latest technology, we hope to gain better insight into how disturbances of the microbiota cause disease, alter immune function and interact with the human genome. This knowledge is essential to enable future possible microbiota manipulation in childhood and prevention of disease.

Neuroblastoma Classification Biology Studies